Gunderson Dettmer advised ARMO BioSciences, Inc. on its initial public offering of 8,658,823 shares at the price to the public of $17.00 per share for a total of $147,199,991 in aggregate gross proceeds. Corporate partner Marcia Hatch, IPOs and equity capital markets partner Richard Blake, and associates Colin Coklin, Sogol Salari and Elaine Strand Sylvester led the team advising ARMO.

The underwriting syndicate included Jefferies, Leerink Partners, BMO Capital Markets and Baird.

ARMO, which trades on the Nasdaq under the ticker symbol “ARMO,” is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors.